Harvard Bioscience Secures $40 Million Financing
In a significant move to bolster its financial standing, Harvard Bioscience, Inc. (NASDAQ: HBIO) has successfully finalized an agreement with BroadOak Capital Partners. This partnership will provide the company with a comprehensive $40 million credit facility, effectively designed to facilitate the retirement of existing debt and to enhance its capital structure.
Key Features of the Financing Package
The financing consists of three distinct term loans, with Term Loan A and Term Loan B collectively yielding $32.5 million. Additionally, Term Loan C, a convertible option, is set at $7.5 million, offering the flexibility to convert into shares at a defined price. All loans have a maturity date set for December 17, 2029, providing ample time for planned repayments and growth initiatives. Furthermore, the Company can extend both the maturity date and the start of its principal payments based on the achievement of specific financial milestones.
John Duke, CEO of Harvard Bioscience, expressed his enthusiasm regarding this funding agreement, indicating that it significantly enhances the company’s financial flexibility and stability for future endeavors. “By refinancing our near-term obligations, we can pivot toward executing our strategic objectives,” he stated.
Enhancing Governance and Strategic Focus
In alignment with the new financing, Harvard Bioscience will also undergo governance enhancements. Bill Snider, a partner at BroadOak, has joined the Company’s board of directors. With over 30 years of experience in investment roles, his background in life sciences will serve as an asset as the company navigates growth and operational landscapes.
Formation of an Advisory Board
Moreover, Harvard Bioscience is set to establish a dedicated Advisory Board that will include industry experts aimed at improving the company’s commercial potential and operational efficiency. This advisory board will focus on key areas such as product planning, lifecycle management, and overall business strategy.
Future Growth Initiatives
Bill Snider articulates confidence in the company’s ability to thrive with the new financing and organizational changes. He recognizes that Harvard Bioscience stands at the forefront of various innovations in research methodologies, aligning closely with regulatory advancements.
In conclusion, with this robust financing and a strategic board comprised of experienced industry leaders, Harvard Bioscience is well-equipped to foster its mission and strengthen its position within the life sciences sector.
About Harvard Bioscience
Harvard Bioscience, Inc. is a prominent player in the development, manufacturing, and marketing of technologies that drive advancements in life sciences. The company serves a variety of clients including leading academic institutions, governmental research entities, and major pharmaceutical companies.
For those interested in learning more, please visit www.harvardbioscience.com.
Frequently Asked Questions
What financing has Harvard Bioscience recently secured?
Harvard Bioscience has finalized a $40 million credit facility with BroadOak Capital Partners to enhance its financial flexibility.
Who has joined the board of directors at Harvard Bioscience?
Bill Snider, a partner at BroadOak, has joined the Company’s board as part of the new financing agreement.
What is the purpose of the new financing?
The financing is aimed at retiring existing debts and improving the company’s capital structure for future growth.
What role will the Advisory Board have?
The Advisory Board will provide guidance on operational opportunities and strategic initiatives to enhance Harvard Bioscience’s market position.
How does this financing support the company's operations?
This financial package will enable Harvard Bioscience to execute its strategic priorities and strengthen its operational capacity.
